Daily doses of rosuvastatin 40 mg monotherapy reduced low-density lipoprotein (LDL) cholesterol and non-HDL cholesterol levels significantly more than did either ER niacin 2 g monotherapy or ...

Rosuvastatin would be associated with a reduction in first major cardiovascular events, as compared with placebo, in apparently healthy patients with LDL <130 mg/dl, but hs-CRP ≥2 mg/L.